Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared on X:
“Myeloma Paper of the Day:
Subgroup analysis of LINKER-MM1 in RRMM finds response rates in non-frail and frail groups, respectively: IMWG-FP, 72.7% and 65.6%; SFS, 69.8% and 74.2%; PRFP, 73.0% and 62.5%; Grade 3/4 TEAEs consistent across non-frail and frail.”
Title: Linvoseltamab outcomes by frailty status in patients with relapsed/refractory multiple myeloma: a subgroup analysis of the LINKER-MM1 study
Authors: Hira Mian, Naresh Bumma, Joshua Richter, Mina Awad, Timothy J. Inocencio, C. Akunna Otele, Megan Seraphin, Tito Roccia, Glenn S. Kroog, Tanya M. Wildes
You can read the full article on Blood Cancer Journal.
You can find other articles featuring Robert Orlowski on OncoDaily.
